<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by the Ethical Medicines Industry Group (EMIG) (RAD004)</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">the Ethical Medicines Industry Group (EMIG) (RAD004)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><img src="data:image/png;base64,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" width="605" height="418" alt="" style="float:left; margin:0pt 9pt" /></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1.0</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The Ethical Medicines Industry Group (EMIG) welcomes this opportunity to </span><span style="font-family:'Times New Roman'; font-size:11pt">submit to the Science and Technology Committee inquiry into </span><span style="font-family:'Times New Roman'; font-size:11pt">Research and Development Funding for Science and Te</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">chnology in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1.2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">EMIG is the research based biopharmaceutical trade association that represents the interests of over 200 companies and o</span><span style="font-family:'Times New Roman'; font-size:11pt">rganisations based in the UK. Our members range from start-ups, whose prime focus is often research and development (R&amp;D), to highly developed businesses delivering essential products to patients and the NHS. They are commonly, but not exclusively, small t</span><span style="font-family:'Times New Roman'; font-size:11pt">o medium-sized enterprise</span><span style="font-family:'Times New Roman'; font-size:11pt">s (SMEs). Less than 20% of our m</span><span style="font-family:'Times New Roman'; font-size:11pt">embers are rep</span><span style="font-family:'Times New Roman'; font-size:11pt">resented by other trade bodies.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1.3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK life sciences industry provides vital medicines to patients, is at the forefront of medical innovation and is a significant contributor to </span><span style="font-family:'Times New Roman'; font-size:11pt">the UK economy.  SMEs constitute approximately 90% of the total number of biopharmaceutical companies and it is estimated that 80% of innovation is derived from these small companies. EMIG member companies employ approximately 20,000 people in the UK and h</span><span style="font-family:'Times New Roman'; font-size:11pt">ave a combined annual turnover of £4</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">b</span><span style="font-family:'Times New Roman'; font-size:11pt">illio</span><span style="font-family:'Times New Roman'; font-size:11pt">n.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1.4</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">EMIG would be delighted to give oral evidence to the Select Committee if it would be valuable or if any of the points in this submission require further detail. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.0</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">National Audit Office (NAO) review</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> Research and Development funding for science and technology in the UK</span></p><p style="font-size:11pt; line-height:120%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The National Audit Office’s (NAO) report highlights the significant spend of t</span><span style="font-family:'Times New Roman'; font-size:11pt">he UK pharmaceuticals sector</span><span style="font-family:'Times New Roman'; font-size:11pt"> on R&amp;D and </span><span style="font-family:'Times New Roman'; font-size:11pt">its contribution </span><span style="font-family:'Times New Roman'; font-size:11pt">as a ‘key driver to innovation in the UK’. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ho</span><span style="font-family:'Times New Roman'; font-size:11pt">wever, EMIG shares the NAO’s concerns that the sector is heavily dependent upon two large pharmaceutical companies</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">GlaxoSmithKline and AstraZeneca</span><span style="font-family:'Times New Roman'; font-size:11pt">. It is imperative the life sciences industry is able to continue to grow and contribute to th</span><span style="font-family:'Times New Roman'; font-size:11pt">e UK economy bu</span><span style="font-family:'Times New Roman'; font-size:11pt">t to continue to do so by relying sp</span><span style="font-family:'Times New Roman'; font-size:11pt">ecifically </span><span style="font-family:'Times New Roman'; font-size:11pt">on </span><span style="font-family:'Times New Roman'; font-size:11pt">these two major companies, is deemed, quite rightly, risky.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.2</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">It is therefore vital that the UK fosters a regulatory, fiscal and commercial environment which enables a new generation of companies to become significant R&amp;D funders. SMEs in the sector </span><span style="font-family:'Times New Roman'; font-size:11pt">are particularly exposed to the current economic downturn and the un</span><span style="font-family:'Times New Roman'; font-size:11pt">certainty caused by the current domestic environment. However, SMEs are essential to the economy as when they launch new products, they grow organically and additionally outsource many of their service requirements, stimulating a hinterland of service comp</span><span style="font-family:'Times New Roman'; font-size:11pt">anies that contribute to employment and the economy. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.3</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">As SMEs</span><span style="font-family:'Times New Roman'; font-size:11pt"> typically lack the resources required to conduct all</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the necessary steps, from basic research to marketing, </span><span style="font-family:'Times New Roman'; font-size:11pt">they</span><span style="font-family:'Times New Roman'; font-size:11pt"> tend to focus their R&amp;D in a</span><span style="font-family:'Times New Roman'; font-size:11pt"> well-defined and narrow field, for example specific indications or pharmaceutical formulations. They also, therefore, frequently out-license or sell their innovations to larger companies. Currently, approximately 25 per cent of the molecules in the develo</span><span style="font-family:'Times New Roman'; font-size:11pt">pment portfolios of large pharmaceutical companies have been acquired from other comp</span><span style="font-family:'Times New Roman'; font-size:11pt">anies, many of which are SMEs. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is therefore critical that specific measures to nourish and support these companies and their associates are recognised and implemented.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 31.2pt; text-indent:-31.2pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.4</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">EMIG welcomes the support for the sector </span><span style="font-family:'Times New Roman'; font-size:11pt">through measure</span><span style="font-family:'Times New Roman'; font-size:11pt">s contained in the Life Sciences Strategy and recent funding for initiatives including the Specialised Services Commissioning Innovation Fund and the </span><span style="font-family:'Times New Roman'; font-size:11pt">Biomedical Catalyst Fund</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The Government has</span><span style="font-family:'Times New Roman'; font-size:11pt"> also made important strides in fostering a more positive tax environment for the life sciences industry in the UK. Over the last 24 months there have been some welcome changes, in particular, the reduction in business tax rates, the introduction of the Pa</span><span style="font-family:'Times New Roman'; font-size:11pt">tent Box, R&amp;D above the line tax credits and the Seed Enterprise Investment Scheme (SEIS) and changes to Enterprise Management Incentives (EMI). However, we believe the following areas require further consideration: </span></p><ul type="square" style="margin:0pt; padding-left:0pt"><li style="font-family:Wingdings; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 45.48pt; padding-left:11.22pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To support the UK’s aim to provide a world class environment for science and to attract high calibre people and the retention of high value jobs we believe it is important to look at tax incentives. Tax incentives do not currently lend themselves naturally</span><span style="font-family:'Times New Roman'; font-size:11pt"> to businesses that are foreign-owned. EMIG members would like to see tax incentives to encourage overseas pharmaceutical companies to invest in the UK as a management centre. </span></li><li style="font-family:Wingdings; font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 45.48pt; padding-left:11.22pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">EMIG would welcome the introduction of incentives for those companies commissio</span><span style="font-family:'Times New Roman'; font-size:11pt">ning medical research or studies. Whilst we recognise there are a number of factors contributing to the decline in medical research in the UK, the current forfeiture of R&amp;D incentives when R&amp;D is outsourced is unhelpful. </span></li><li style="font-family:Wingdings; font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 45.48pt; padding-left:11.22pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Whilst the SEIS, Enterprise Invest</span><span style="font-family:'Times New Roman'; font-size:11pt">ment Scheme (EIS) and Venture Capital Trusts (VCT) provide valuable assistance to SMEs, they can be difficult and complex to access. As </span><span style="font-family:'Times New Roman'; font-size:11pt">such, we would like to see such schemes simplified which will provide companies with clarity and certainty and allow eas</span><span style="font-family:'Times New Roman'; font-size:11pt">ier access. </span></li></ul><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2.5</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The NAO’s report separates</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">spending by independent SMEs,</span><span style="font-family:'Times New Roman'; font-size:11pt"> those</span><span style="font-family:'Times New Roman'; font-size:11pt"> which are not part of a larger enterprise group, </span><span style="font-family:'Times New Roman'; font-size:11pt">from overall SME spend. EMIG is concerned that the </span><span style="font-family:'Times New Roman'; font-size:11pt">report </span><span style="font-family:'Times New Roman'; font-size:11pt">appears to denigrate </span><span style="font-family:'Times New Roman'; font-size:11pt">those SMEs who are R&amp;D investors but happen to </span><span style="font-family:'Times New Roman'; font-size:11pt">be a UK affiliate of a larger global enterprise</span><span style="font-family:'Times New Roman'; font-size:11pt"> from those which are ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">home grown</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> If so, this</span><span style="font-family:'Times New Roman'; font-size:11pt"> risks devaluing the importance of attracting </span><span style="font-family:'Times New Roman'; font-size:11pt">inward investment</span><span style="font-family:'Times New Roman'; font-size:11pt">. EMIG believes b</span><span style="font-family:'Times New Roman'; font-size:11pt">oth </span><span style="font-family:'Times New Roman'; font-size:11pt">independent</span><span style="font-family:'Times New Roman'; font-size:11pt"> and UK affiliate SME funders are important to the nation's econom</span><span style="font-family:'Times New Roman'; font-size:11pt">y.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Suggestions for future Committee inquiries</span></p><p style="font-size:11pt; line-height:120%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 35.7pt; text-indent:-35.7pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">In light of our comments above, EMIG suggests the following </span><span style="font-family:'Times New Roman'; font-size:11pt">for future Committee inquiries on UK R&amp;D funding</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span></p><ul type="square" style="margin:0pt; padding-left:0pt"><li style="font-family:Wingdings; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 45.48pt; padding-left:11.22pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Encouraging SMEs to invest in research and development </span></li></ul><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 56.7pt"><span style="font-family:'Times New Roman'; font-size:11pt">Looking specifically at:</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="font-family:'Courier New'; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 68.3pt; padding-left:16.75pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The measures needed to encourage SMES to invest in R&amp;D; and </span></li><li style="font-family:'Courier New'; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 68.3pt; padding-left:16.75pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The impact of go</span><span style="font-family:'Times New Roman'; font-size:11pt">vernment support to promote </span><span style="font-family:'Times New Roman'; font-size:11pt">research and development</span><span style="font-family:'Times New Roman'; font-size:11pt"> investment of</span><span style="font-family:'Times New Roman'; font-size:11pt"> ‘independent’ SMEs based in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> and UK affiliate SMEs.</span></li></ul><li style="font-family:Wingdings; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 45.48pt; padding-left:11.22pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Public and private partnerships in research and develo</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">pment</span></li></ul><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 56.7pt"><span style="font-family:'Times New Roman'; font-size:11pt">Looking specifically at:</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="font-family:'Courier New'; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 86.3pt; padding-left:6.4pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The m</span><span style="font-family:'Times New Roman'; font-size:11pt">easures </span><span style="font-family:'Times New Roman'; font-size:11pt">needed </span><span style="font-family:'Times New Roman'; font-size:11pt">to encourage </span><span style="font-family:'Times New Roman'; font-size:11pt">public and private partnerships; and</span></li><li style="font-family:'Courier New'; font-size:11pt; line-height:120%; margin:0pt 0pt 6pt 86.3pt; padding-left:6.4pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The potential for novel shared risk/shared reward R&amp;D models between the private and public sectors to support UK plc.</span></li></ul><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt; text-align:right"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>